Answers are grounded in this paper and cite their sources.
Analysis investigates prevalence and survival rates of leukemias in Russia, indicating treatment challenges.
This work represents the second part of a study dedicated to investigating leukemias in Russia. The focus is on the prevalence, dynamics of histological structure, and annual mortality of myeloid (C92), monocytic (C93), and other leukemias (C94-95), as well as the assessment of patient survival. The analysis confirmed the relatively low prevalence of these diseases and the limited progress in improving treatment outcomes over the past two decades. An important aspect is the use of data from the Population-Based Cancer Registry (PBCR) of the Northwestern Federal District (NWFD), which contains information on over 1.6 million observations, including 28.7 thousand cases of leukemia. This allows us to overcome the limitations associated with the predominance of foreign and clinical data in Russian scientific literature. In addition, the results of the survival analysis of patients with lymphoblastic leukemia (C91), conducted taking into account age, sex, and region of residence (a continuation of the first part of the study), are presented. The aim of the study is to investigate the prevalence of myeloid (C92), monocytic (C93), and other leukemias (C94-95) among the population in Russia, the dynamics of detailed histological structure, and annual mortality. To calculate the survival of patients. The conducted study, with an analysis of the prevalence of myeloid and monocytic leukemias, confirmed the rarity of this pathology and the modest success in the treatment of patients. Over the past two decades, patient mortality has remained virtually unchanged.
No takes yet. Share an insight, caveat, or question.
Vm et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: